This report describes and explains the biologics market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global biologics market reached a value of nearly $446.38 billion in 2024, having grown at a compound annual growth rate (CAGR) of 8.23% since 2019. The market is expected to grow from $446.38 billion in 2024 to $653.76 billion in 2029 at a rate of 7.93%. The market is then expected to grow at a CAGR of 7.22% from 2029 and reach $926.23 billion in 2034.
Growth in the historic period resulted from the increasing incidence of autoimmune disorders, expansion of pharmaceutical and biotechnology industries, rising healthcare expenditure and rising demand for personalized medicine. Factors that negatively affected growth in the historic period were high cost of biologic therapies and stringent regulatory standards.
Going forward, the rising prevalence of chronic diseases, increasing research and development investments by pharma companies, rise in aging population and rapid adoption of monoclonal antibodies will drive the growth. Factor that could hinder the growth of the biologics market in the future include cold chain and storage challenges, risk of cross-contamination and impact of trade war and tariff.
The biologics market is segmented by type into monoclonal antibodies (MAbS), therapeutic proteins and vaccines. The monoclonal antibodies (MAbS) market was the largest segment of the biologics market segmented by type, accounting for 54.04% or $241.24 billion of the total in 2024. Going forward, the therapeutic proteins segment is expected to be the fastest growing segment in the biologics market segmented by type, at a CAGR of 10.61% during 2024-2029.
The biologics market is segmented by route of administration into oral, parenteral and other route of administration. The parenteral market was the largest segment of the biologics market segmented by route of administration, accounting for 93.00% or $415.13 billion of the total in 2024. Going forward, the oral segment is expected to be the fastest growing segment in the biologics market segmented by route of administration, at a CAGR of 10.83% during 2024-2029.
The biologics market is segmented by distribution channel into hospital pharmacies, retail pharmacies or drug stores, other distribution channels. The hospital pharmacies market was the largest segment of the biologics market segmented by distribution channel, accounting for 51.38% or $229.33 billion of the total in 2024. Going forward, the retail pharmacies or drug stores segment is expected to be the fastest growing segment in the biologics market segmented by distribution channel, at a CAGR of 8.77% during 2024-2029.
The biologics market is segmented by drug classification into branded drugs and generic drugs. The branded drugs market was the largest segment of the biologics market segmented by drug classification, accounting for 69.13% or $308.59 billion of the total in 2024. Going forward, the generic drugs segment is expected to be the fastest growing segment in the biologics market segmented by drug classification, at a CAGR of 8.50% during 2024-2029.
The biologics market is segmented by mode of purchase into prescription-based drugs and over-the-counter drugs. The prescription-based drugs market was the largest segment of the biologics market segmented by mode of purchase, accounting for 79.35% or $354.2 billion of the total in 2024. Going forward, the over-the-counter drugs segment is expected to be the fastest growing segment in the biologics market segmented by mode of purchase, at a CAGR of 8.35% during 2024-2029.
North America was the largest region in the biologics market, accounting for 52.48% or $234.27 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the biologics market will be Africa and Middle East where growth will be at CAGRs of 11.82% and 10.05% respectively. These will be followed by Asia Pacific and Eastern Europe where the markets are expected to grow at CAGRs of 9.72% and 9.27% respectively.
The global biologics market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 64.61% of the total market in 2024. Pfizer Inc was the largest competitor with a 13.98% share of the market, followed by Merck & Co. Inc with 9.39%, F. Hoffmann-La Roche AG with 8.87%, Johnson & Johnson with 6.61%, Regeneron Pharmaceutical Inc with 5.90%, AbbVie Inc with 4.95%, Sanofi S.A with 4.03%, Amgen Inc with 3.75%, AstraZeneca plc with 3.59% and Bristol Myers Squibb Company with 3.55%.
The top opportunities in the biologics market segmented by type will arise in the monoclonal antibodies (MAbS) segment, which will gain $96.9 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by route of administration will arise in the parenteral segment, which will gain $189.42 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $107.36 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by drug classification will arise in the branded drugs segment, which will gain $138.01 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by mode of purchase will arise in the prescription-based drugs segment, which will gain $161.9 billion of global annual sales by 2029. The biologics market size will gain the most in the USA at $96.33 billion.
Market-trend-based strategies for the biologics market include focus on enhancing access to anti-angiogenic therapies via biosimilars, focus on enhancing access to biologic therapies in autoimmune segments, focus on supporting disease management with affordable biologic solutions, focus on advancing high-concentration biologic formulations and focus on enhancing delivery efficiency in advanced therapies.
Player-adopted strategies in the biologics market include focus on expanding business capabilities through strategic investment to expand its operational capabilities.
To take advantage of the opportunities, the analyst recommends the biologics market companies to focus on biosimilar integration to expand access and portfolios, focus on expanding biosimilar integration to drive accessibility and growth, focus on expanding biosimilar portfolios to drive growth, focus on high-concentration formulation platforms, focus on viral vector platforms to drive gene therapy growth, focus on therapeutic proteins for accelerated growth, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use b2b promotions, focus on retail pharmacies for sustained growth, focus on the over-the-counter drugs segment.
This product will be delivered within 3-5 business days.
The global biologics market reached a value of nearly $446.38 billion in 2024, having grown at a compound annual growth rate (CAGR) of 8.23% since 2019. The market is expected to grow from $446.38 billion in 2024 to $653.76 billion in 2029 at a rate of 7.93%. The market is then expected to grow at a CAGR of 7.22% from 2029 and reach $926.23 billion in 2034.
Growth in the historic period resulted from the increasing incidence of autoimmune disorders, expansion of pharmaceutical and biotechnology industries, rising healthcare expenditure and rising demand for personalized medicine. Factors that negatively affected growth in the historic period were high cost of biologic therapies and stringent regulatory standards.
Going forward, the rising prevalence of chronic diseases, increasing research and development investments by pharma companies, rise in aging population and rapid adoption of monoclonal antibodies will drive the growth. Factor that could hinder the growth of the biologics market in the future include cold chain and storage challenges, risk of cross-contamination and impact of trade war and tariff.
The biologics market is segmented by type into monoclonal antibodies (MAbS), therapeutic proteins and vaccines. The monoclonal antibodies (MAbS) market was the largest segment of the biologics market segmented by type, accounting for 54.04% or $241.24 billion of the total in 2024. Going forward, the therapeutic proteins segment is expected to be the fastest growing segment in the biologics market segmented by type, at a CAGR of 10.61% during 2024-2029.
The biologics market is segmented by route of administration into oral, parenteral and other route of administration. The parenteral market was the largest segment of the biologics market segmented by route of administration, accounting for 93.00% or $415.13 billion of the total in 2024. Going forward, the oral segment is expected to be the fastest growing segment in the biologics market segmented by route of administration, at a CAGR of 10.83% during 2024-2029.
The biologics market is segmented by distribution channel into hospital pharmacies, retail pharmacies or drug stores, other distribution channels. The hospital pharmacies market was the largest segment of the biologics market segmented by distribution channel, accounting for 51.38% or $229.33 billion of the total in 2024. Going forward, the retail pharmacies or drug stores segment is expected to be the fastest growing segment in the biologics market segmented by distribution channel, at a CAGR of 8.77% during 2024-2029.
The biologics market is segmented by drug classification into branded drugs and generic drugs. The branded drugs market was the largest segment of the biologics market segmented by drug classification, accounting for 69.13% or $308.59 billion of the total in 2024. Going forward, the generic drugs segment is expected to be the fastest growing segment in the biologics market segmented by drug classification, at a CAGR of 8.50% during 2024-2029.
The biologics market is segmented by mode of purchase into prescription-based drugs and over-the-counter drugs. The prescription-based drugs market was the largest segment of the biologics market segmented by mode of purchase, accounting for 79.35% or $354.2 billion of the total in 2024. Going forward, the over-the-counter drugs segment is expected to be the fastest growing segment in the biologics market segmented by mode of purchase, at a CAGR of 8.35% during 2024-2029.
North America was the largest region in the biologics market, accounting for 52.48% or $234.27 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the biologics market will be Africa and Middle East where growth will be at CAGRs of 11.82% and 10.05% respectively. These will be followed by Asia Pacific and Eastern Europe where the markets are expected to grow at CAGRs of 9.72% and 9.27% respectively.
The global biologics market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 64.61% of the total market in 2024. Pfizer Inc was the largest competitor with a 13.98% share of the market, followed by Merck & Co. Inc with 9.39%, F. Hoffmann-La Roche AG with 8.87%, Johnson & Johnson with 6.61%, Regeneron Pharmaceutical Inc with 5.90%, AbbVie Inc with 4.95%, Sanofi S.A with 4.03%, Amgen Inc with 3.75%, AstraZeneca plc with 3.59% and Bristol Myers Squibb Company with 3.55%.
The top opportunities in the biologics market segmented by type will arise in the monoclonal antibodies (MAbS) segment, which will gain $96.9 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by route of administration will arise in the parenteral segment, which will gain $189.42 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $107.36 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by drug classification will arise in the branded drugs segment, which will gain $138.01 billion of global annual sales by 2029. The top opportunities in the biologics market segmented by mode of purchase will arise in the prescription-based drugs segment, which will gain $161.9 billion of global annual sales by 2029. The biologics market size will gain the most in the USA at $96.33 billion.
Market-trend-based strategies for the biologics market include focus on enhancing access to anti-angiogenic therapies via biosimilars, focus on enhancing access to biologic therapies in autoimmune segments, focus on supporting disease management with affordable biologic solutions, focus on advancing high-concentration biologic formulations and focus on enhancing delivery efficiency in advanced therapies.
Player-adopted strategies in the biologics market include focus on expanding business capabilities through strategic investment to expand its operational capabilities.
To take advantage of the opportunities, the analyst recommends the biologics market companies to focus on biosimilar integration to expand access and portfolios, focus on expanding biosimilar integration to drive accessibility and growth, focus on expanding biosimilar portfolios to drive growth, focus on high-concentration formulation platforms, focus on viral vector platforms to drive gene therapy growth, focus on therapeutic proteins for accelerated growth, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use b2b promotions, focus on retail pharmacies for sustained growth, focus on the over-the-counter drugs segment.
This product will be delivered within 3-5 business days.
Executive Summary
Biologics Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global biologics market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for biologics ? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The biologics market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider biologics market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by drug classification, by route of administration, by mode of purchase and by distribution channel.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by drug classification, by route of administration, by mode of purchase and by distribution channel in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size And Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments - Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for biologics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Monoclonal Antibodies (MABS); Therapeutic Proteins; Vaccines2) By Drug Classification: Branded Drugs; Generic Drugs
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
4) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies Or Drug Stores; Other Distribution Channels
Companies Mentioned:Pfizer Inc.; Merck & Co. Inc.; F. Hoffmann-La Roche AG; Johnson & Johnson; Regeneron Pharmaceutical Inc.
Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Regions:Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; biologics indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Regeneron Pharmaceutical Inc.
- AbbVie Inc.
- Sanofi S.A.
- Amgen Inc.
- AstraZeneca plc
- Bristol Myers Squibb Company
- Innovent Biologics
- Hengrui Pharma
- Biocon
- Indian Immunologicals Ltd (IIL)
- Dr. Reddy’s Laboratories
- Serum Institute of India
- Zydus Cadila
- Takeda Pharmaceutical
- Daiichi Sankyo
- Chugai Pharmaceutical (Roche subsidiary)
- Samsung Biologics
- Xbrane Biopharma AB
- STADA
- Celltrion
- LG Chem Life Sciences
- CSL Limited
- Patheon (Thermo Fisher Scientific)
- Lonza Biologics
- Tessa Therapeutics
- EnteroBiotix
- Lonza Group AG
- Sartorius AG
- Bio-Rad Laboratories
- Eppendorf AG
- Miltenyi Biotec B.V. & Co. KG
- Cytena GmbH
- GE HealthCare
- SGS S.A.
- Aenitis Technologies
- Bracco S.p.A.
- Gilead Sciences
- Renuron Group
- Siemens Healthineers AG
- Cytiva Europe GmbH
- bioMérieux
- Immersciobio GmbH
- Ciloa
- Differential Bio
- GlaxoSmithKline Plc
- Lilly
- Teva Limited
- Abbott Laboratories
- Vectura Group Limited
- Procos S.p.A.
- BSP Pharmaceuticals S.p.A.
- 4Moving Biotech
- Coriolis Pharma
- Chiesi Farmaceutici S.p.A.
- EXO Biologics
- Chime Biologics
- Polpharma Biologics
- Bioton
- Mabion
- Richter Gedeon
- Egis Pharmaceuticals
- SOTIO
- Zentiva
- Wacker Chemie AG
- Forge Biologics Holdings LLC
- LOTTE Biologics
- Pinnacle Biologics
- Alvotech
- Ultragenyx Pharmaceutical Inc.
- Eurofins CDMO Alphora
- Formycon AG
- Fresenius Kabi
- Viatris Inc.
- Abzena
- Biotimize
- Richmond Pharmaceuticals
- BioMarin Pharmaceutical
- Bionovis
- Artixio
- MediWound Ltd
- Tabuk Pharmaceuticals
- SaudiVax
- Pfizer
- Kemwell
- Juniper Biologics Pte Ltd
- Afrigen Biologics and Vaccines
- EVA Pharma
- Dei BioPharma Ltd
- Aspen Pharmacare
